Venrock Healthcare Capital Partners II, L.P. 13D and 13G filings for Trevi Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-14 6:04 pm Sale |
2024-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Venrock Healthcare Capital Partners II, L.P. | 1,266,457 1.400% |
-6,410,477 (-83.50%) |
Filing |
| 2024-11-14 5:51 pm Purchase |
2024-09-30 | 13G | Trevi Therapeutics, Inc. TRVI |
Venrock Healthcare Capital Partners II, L.P. | 7,676,934 9.990% |
969,370 (+14.45%) |
Filing |
| 2024-02-14 8:47 pm Purchase |
2023-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Venrock Healthcare Capital Partners II, L.P. | 6,707,564 9.990% |
395,372 (+6.26%) |
Filing |
| 2023-02-14 4:55 pm Purchase |
2022-12-31 | 13G | Trevi Therapeutics, Inc. TRVI |
Venrock Healthcare Capital Partners II, L.P. | 6,312,192 9.990% |
2,643,858 (+72.07%) |
Filing |
| 2022-04-21 4:05 pm Purchase |
2022-04-11 | 13G | Trevi Therapeutics, Inc. TRVI |
Venrock Healthcare Capital Partners II, L.P. | 3,668,334 9.990% |
3,668,334 (New Position) |
Filing |